Медицинская литература. Новинки

 

 

 

 

 

 

ПЭТ/КТ с 18F-ФДГ и 18F-холином в комплексной диагностике диссеминированного гепатоцеллюлярного рака у пациента семи лет (клиническое наблюдение)

Вы можете загрузить полный текст статьи в формате pdf

Представлен редкий случай диссеминированного гепатоцеллюлярного рака у пациента детского возраста с использованием ПЭТ/кТ с 18F-холином и 18F-фтордезоксиглюкозой и МРТ с внутривенным контрастированием гепатотропным препаратом “Мультихэнс”. Получены данные о наличии метастатического поражения левого легкого и правой доли печени. Выявлены различия в накоплении 18F-холина и 18F-фтордезоксиглюкозы в метастазах гепатоцеллюлярного рака. ПЭТ/КТ с 18F-холином показала высокую чувствительность в диагностике метастазов высокодифференцированного гепатоцеллюлярного рака и может успешно использоваться в детском возрасте.

Ключевые слова:
ПЭТ/КТ, 18F-холин, 18F-фтордезоксиглюкоза, МРТ, гепатоцеллюлярный рак, PET/CT, 18F-choline, 18F-fluorodeoxyglucose, MRI, hepatocellular carcinoma

Литература:
1.Kelly D. Hepatocellular Carcinoma in Children. Clin. Liver Disease. 2015; 19 (2): 433-447.
2.Perlmutter D.H. Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency. Pediatr. Res. 2006; 60 (2): 233-238.
3.Моногарова Н.Е., Мороз Т.В. Недостаточность альфа-1-антитрипсина. Новости медицины и фармации. 2009; 304: 12-73.
4.Labrune P., Trioche P., Duvaltier I. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J. Pediatr. Gastroenterol. Nutr. 1997; 24 (3): 276-279.
5.Chen Y.T., Burchell A. Glycogen storage diseases. Harrison''s Principles Intern. Med. 1998: 2176-2182.
6.Weinberg A.G., Mize C.E., Worthen H.G. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J. Pediatr. 1976; 88 (3): 434-438.
7.Davit-Spraul A., Gonzales E., Baussan C. Progressive familial intrahepatic cholestasis. Orphanet J. Rare Dis. 2009; 4 (1): 12-24.
8.Reuben A. Hepatocellular carcinoma in adults and children. Clin. Liver Dis. 2015; 19 (2): 8-19.
9.Iwatsuki S., Sheahan D., Yokoyama I. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann. Surg. 1991; 214 (3): 221-228.
10.Ikeda M., Okada S., Ueno H. Radiofrequency ablation and percutaneous ethanol injection in patients with small hepatocellular carcinoma: a comparative study. Jap. J. Clin. Oncol. 2001; 31 (7): 322-326.
11.Tagge E.P., Tagge D.U., Reyes J. Resection, including transplantation, for hepatoblastoma and hepatocellular carcinoma: impact on survival. J. Pediatr. Surg. 2009; 27 (3): 292-297.
12.Zen Y., Vara R., Portmann B. Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM. Histopathology. 2014; 64 (5): 671-682.
13.Caturelli E. et al. Hemangioma-like lesions in chronic liver disease: diagnostic evaluation in patients 1. Radiology. 2001; 220 (2): 337-342.
14.Matsui O., Kadoya M., Kameyama T. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology. 1991; 178 (2): 493-497.
15.Fracanzani A.L., Burdick L., Borzio M. Contrast-enhanced Doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology. 2001; 34 (6): 1109-1112.
16.Colli A., Fraquelli M., Casazza G. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alphafetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am. J. Gastroenterol. 2006; 101 (3): 513-523.
17.Wilson S.R., Burns P.N. An algorithm for the diagnosis of focal liver masses using microbubble contrastenhanced pulse-inversion sonography. Am. J. Roentgenol. 2006; 186 (5): 1401-141.
18.European Association For The Study Of The Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56 (4): 908-943.
19.Forner A., Vilana R., Ayuso C. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective valida tion of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008; 47 (1): 97-104.
20.Breedis C., Young G. The blood supply of neoplasms in the liver. Am. J. Pathol. 1954; 30 (5): 969-985.
21.Baron R.L., Nalesnik M., Holbert B.L. Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. Radiology. 1996; 199 (2): 505-511.
22.Кармазановский Г.Г., Шимановский Н.Л. Диагностическая эффективность нового магнитно-резонансного контрастного средства “Примовист” (гадоксетовая кислота) при выявлении первичных и вторичных опухолей печени. Медицинская визуализация. 2007; 6: 135-143.
23.Терновой С.К., Шахиджанова С.В. Магнитно-резонансная томография в диагностике очаговых заболеваний печени (обзор литературы). Медицинская визуализация. 1999; 3: 24-27.
24.Лукьянченко А.Б., Медведева Б.М. Магнитно-резонанс ная томография в диагностике и дифференциальной диагностике очаговых поражений печени. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2004; 15 (1): 2.
25.Jeong Y.Y., Yim N.Y., Kang H.K. Hepatocellular carcinoma in the cirrhotic liver with helical CT and MRI: imaging spectrum and pitfalls of cirrhosis-related nodules. Am. J. Roentgenol. 2005; 185 (4): 1024-1032.
26.Lee M.H., Kim S.H., Park M.J. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusionweighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. Am. J. Roentgenol. 2011; 197 (5): 868-875.
27.Лукьянченко А.Б., Медведева Б.М. Современная тактика распознавания новообразований печени. Издательская группа РОНЦ; Практическая медицина. 2015; 87-91.
28.Delbeke D., Martin W.H., Sandler M.P. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch. Surg. 1998; 133 (5): 510-516.
29.Trojan J., Schroeder O., Raedle J. Fluorine-18 FDG positron emission tomography for imaging of hepato cellular carcinoma. Am. J. Gastroenterol. 1999; 94 (11): 3314-3319.
30.Talbot J.N., Gutman F., Fartoux L. PET/CT in patients with hepatocellular carcinoma using [18F] fluorocholine: preliminary comparison with [18F] FDG PET/CT. Eur. J. Nucl. Med. Molecular Imaging. 2006; 33 (11): 1285-1289.
31.Yamamoto Y., Nishiyama Y., Kameyama R. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J. Nuclear Med. 2008; 49 (8): 1245-1248.
32.Hwang K.H., Choi D.J., Lee S.Y. Evaluation of patients with hepatocellular carcinomas using [11C] acetate and [18F] FDG PET/CT: A preliminary study. Applied Radiation and Isotopes. 2009; 67 (7): 1195-1198.
33.Lee J.W., Paeng J.C., Kang K.W. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J. Nuclear Med. 2009; 50 (5): 682-687.
34.Talbot J.N., Fartoux L., Balogova S. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J. Nuclear Med. 2010; 51 (11): 1699-1706.
35.van den Esschert J.W., Bieze M., Beuers U.H. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using 18F-fluorocholine PET/CT. Eur. J. Nucl. Med. Molecular Imaging. 2011; 38 (3): 436-440.
36.Kuang Y., Salem N., Tian H. Imaging lipid synthesis in hepatocellular carcinoma with [methyl-11C] choline: correlation with in vivo metabolic studies . J. Nuclear Med. 2011; 52 (1): 98-106.
37.Cahill G.F., Ashmore J., Renold A.E. Blood glucose and the liver . Am. J. Med. 1959; 26 (2): 264-282.
38.Hers H.G. The control of glycogen metabolism in the liver. Ann. Rev. Biochemistry. 1976; 44 (1): 167-190.
39.Nordlie R.C., Foster J.D., Lange A.J. Regulation of glucose production by the liver. Ann. Rev. Nutrition. 1999; 19 (1): 379-406.
40.Lee J.D., Yang W.I., Park Y.N. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased 18F-FDG uptake. J. Nucl. Med. 2005; 46 (10): 1753-1759.
41.Paudyal B., Oriuchi N., Paudyal P. Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma. Ann. Nuclear Med. 2008; 22 (1): 83-86.
42.Sorensen M., Frisch K., Bender D. The potential use of 2-[18F] fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma. Eur. J. Nuclear Med. Molec. Imaging. 2011; 38 (9): 1723-1731.
43.Pritchard P. H., Vance D. E. Choline metabolism and phosphatidylcholine biosynthesis in cultured rat hepatocytes. Biochem. J. 1981; 196: 261-267.
44.Ackerstaff E., Glunde K., Bhujwalla Z.M. Choline phospholipid metabolism: a target in cancer cells? J. Cell. Biochem. 2003; 90 (3): 525-533.
45.Aoyama C., Liao H., Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Progress Lipid Res. 2004; 43 (3): 266-281.
46.Kent C. Regulatory enzymes of phosphatidyl choline biosynthesis: a personal perspective. Biochimicaet Biophysica Acta (BBA)-Molecular and Cell. Biology of Lipids. 2005; 1733 (1): 53-66.
47.Kuang Y., Salem N., Corn D. J. Transport and metabolism of radiolabeled choline in hepatocellular carcinoma. Molec. Pharmaceutics. 2010; 7 (6): 2077-2092.
48.Ringe K.I., Husarik D.B., Sirlin C.B. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. Am. J. Roentgenol. 2010; 195 (1): 13-28.
49.Jhaveri K., Cleary S., Audet, P., Balaa F. Сonsensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid). Am. J. Roentgenol. 2015; 204 (3): 498-509.

PET/CT witH 18F-FDG and 18F-Choline in the Complex Diagnostics of Disseminated Hepatocellular Cancer in the Patient Seven Years Old (Clinical Case)

The rare case of disseminated hepatocellular cancer in 7-year-old male patient has been analyzed using PET/CT with 18F-choline and 18F-FDG and mRi with intravenous hepatotropic agent (“MultiHance”). Data confirming the presence of metastatic lesions of the left lung and the right lobe of the liver were obtained. Differences in the uptake of 18F-choline and 18F-fluorodeoxyglucose in the metastasis of hepatocellular carcinomahave been detected. PET/CT with 18F-choline showed a high sensitivity in the diagnosis of metastatic highly differentiated hepatocellular carcinoma. PET/CT can be used successfully in the diagnosis of hepatocellular carcinoma in pediatric patients.

Keywords:
ПЭТ/КТ, 18F-холин, 18F-фтордезоксиглюкоза, МРТ, гепатоцеллюлярный рак, PET/CT, 18F-choline, 18F-fluorodeoxyglucose, MRI, hepatocellular carcinoma